AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer

ZURICH, Sept. 25, 2025 /PRNewswire/ -- AL-S Pharma announced today that it has appointed Angela Genge, MD, Professor of Neurology at McGill University in Montreal, as Chief Medical Officer (CMO). With a distinguished record in amyotrophic lateral sclerosis (ALS) research and the Head of ALS Global Centre of Excellence for Research and Patient Care at McGill, Dr. Genge will join the company's executive team to further develop AP-101 for the treatment of ALS. Since 2016, Dr. Genge has served as the global principal investigator for the Phase 1 and Phase 2 clinical development of AP-101, a first-in-class investigational antibody targeting misfolded SOD1. The company recently reported positive topline Phase 2 study results of AP-101 for the treatment of ALS (press release Sept 4, 2025).

"We are very happy to welcome Prof. Dr. Genge in an expanded role at this exciting time for AL-S Pharma," said Michael Salzmann, PhD, Chief Executive Officer of AL-S Pharma. "As an internationally recognized leader in ALS, Prof. Dr. Genge's expertise will be pivotal to guide our AP-101 late-stage development. Together, we look forward to advancing this potential first-in-class, disease-modifying therapy for ALS."

Angela Genge, MD, FRCP, is a recognized leader in ALS clinical research and drug development. She has served as global principal investigator on pivotal ALS trials, advised regulatory authorities, and participated in more than 80 global clinical advisory boards and trial steering committees. Her contributions have been recognized with prestigious awards such as the Forbes Norris Award, the PACTALS Excellent Research Award, and the Wings Over Wall Street Diamond Award. 

"AL-S Pharma's commitment to develop AP-101 as a first-in-class therapy targeting misfolded SOD1, a key driver of disease-progression, has always impressed me," said Dr. Genge. "I am very much looking forward to working together with the leadership team to further advance the clinical development in an effort to bring this innovative therapy to patients."

In 2016, Neurimmune and TVM Capital Life Science co-created AL-S Pharma AG to develop AP-101. AL-S Pharma has executed its innovative clinical plan for AP-101 in collaboration with an international network of ALS experts. The company recently completed a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in both patients with sporadic ALS (N=52) and patients with mutant SOD1-ALS (N=21) over 24 weeks followed by a 24-week open-label extension and a safety follow-up period. Further information on the clinical study of AP-101 for ALS can be accessed on ClinicalTrials.gov (study number NCT05039099).

About AP-101
AP-101 is an investigational human antibody directed against misfolded superoxide dismutase 1 (SOD1) and was discovered by Neurimmune's Reverse Translational Medicine^TM (RTM^TM) technology. The antibody has been designed to inhibit the spread of SOD1 pathology in the cerebrospinal fluid and spinal cord of ALS patients. AP-101 received orphan drug designations from FDA, EMA and Swissmedic. The Phase 2 study completed by AL-S Pharma evaluated the safety, tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and patients with mutations in the SOD1 gene.

About AL-S Pharma AG
AL-S Pharma is a Swiss-based single-asset company founded and co-owned by Neurimmune and TVM Capital Life Science to develop AP-101. The company is fully financed by TVM Life Science Innovation I and Neurimmune. AL-S Pharma is led by an experienced management team and the Board of Directors comprises Guy Rouleau, director of McGill University's Montreal Neurological Institute (MNI) and Hospital, Chair Department of Neurology and Neurosurgery, McGill University, Hubert Birner, Managing Partner, TVM Capital Life Science, Munich, Marc Riviere, General Partner, TVM Capital Life Science, Montreal, Christoph Hock, CMO of Neurimmune, and Jan Grimm, CSO of Neurimmune.

Follow AL-S Pharma on LinkedIn.

About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. With its Reverse Translational Medicine^TM technology, Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220) for ATTR cardiomyopathy, the anti-SOD1 antibody AP-101 for ALS and the anti-NogoA antibody NG004 for spinal cord injury, programs being currently evaluated in clinical trials.

For further information, please visit www.neurimmune.com. Follow Neurimmune on LinkedIn.

About TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM's portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment. This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Contact for Media

John Capodanno (US)
[email protected]
+1 917 750-8649

Contact for AL-S Pharma
Dr. Michael Salzmann
[email protected]

SOURCE AL-S Pharma AG